Why Is Emergent BioSolutions Stock Down Today?

Emergent BioSolutions (EBS) cut its full-year 2026 sales guidance to $645-675 million, down from $720-760 million, even as the company reported Q2 revenue of $234.3 million — up 66% year-over-year and above the high end of its own prior Q2 guidance. A strong quarter followed by a lower full-year outlook usually means one part of the business is struggling even as another part is outperforming, and that is exactly the pattern here.

Emergent develops medical countermeasures against biological, chemical, radiological, and nuclear threats for government biodefense stockpiles, and separately markets NARCAN, the naloxone nasal spray used to reverse opioid overdoses. CEO Joe Papa said the company delivered a strong second quarter, significantly exceeding the high end of its guidance range, primarily driven by accelerated biodefense contract modifications secured with the U.S. government. That is the part of the business performing well. The part dragging on the full-year outlook is naloxone: NARCAN revenue fell $15.1 million, down 22% year-over-year, and the company booked a $191.3 million non-cash impairment charge tied to that business, producing a net loss of $180.2 million for the quarter even as adjusted net income rose 134% to $30.9 million.

Alongside the guidance cut, Emergent announced a restructuring plan targeting roughly $40 million in annualized savings. Papa described the company as being at a critical juncture in its turnaround, stemming specifically from the naloxone business — language that points to competitive and pricing pressure in the over-the-counter naloxone market as the reason behind both the impairment and the lowered outlook, even as the government biodefense side of the business is growing fast.